




**Stock information**

TASE: HDST, OTC: HADSY  
 IPO: 2006  
 Last round: Aug. 2010  
 Raised to date: over 100 M NIS  
 Index: Biomed, Mid Cap TA, Tel-Tech and others

**Investing in Hadassah Based Biotech Companies**

Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for the majority of Israel's hospital-based translational research. In mid 2011 an American Depositary Receipt (ADR) was initiated (OTC: HADSY) to further expand HBL's investor base enabling domestic trading of the TASE shares in the US. The HBL traded stock, as a unique investment vehicle, provides investment exposure to a select portfolio of 7 biotech companies - all based on inventions developed and owned by Hadassah. The companies operate in the fields of Oncology (Rx and Dx), Regenerative Medicine and Inflammatory Disease. HBL focuses on funding the preparation for and execution of Phase I and preparation for Phase II by the portfolio companies. Preparations include pre-clinical trials, manufacturing, regulatory and business development tasks. By being closely linked to Hadassah, HBL utilizes a competitive advantage symbolized as triple "I": Innovation, Infrastructure & Investment.

**Stockholders**



**Strategy**

HBL focuses on advancing companies that have already shown proof of concept and successful preclinical trials to completion of Phase I and preparation for Phase II. Success in either of these stages can multiply the valuation of each company up to 10X for each milestone. Hadasit, one of HBL's key share holders, wholly owned by Hadassah University Hospital, has founded since its establishment over 20 companies based on a unique model under which it receives substantial equity holdings in exchange for the technology licensed to the company.


HBL has holdings in 7 of those companies all of which met the above criteria and were the most promising. 4 of the companies are already in clinical trials and major biotech firms have been brought in as investors and collaborators. In recent years, potential collaborators (big pharma) have been increasingly more interested in biotech companies in early clinical stages and are spending significantly higher amounts on licensing agreements.

**Management**

Adv. Ophir Shahaf, CEO

Mr. Shahaf is responsible for all of the ongoing activities of the public entity, including financial, legal, IR/PR, investment and fundraising issues. Prior to this position, he served as VP business development at Protalix Biotherapeutics Ltd., a biopharmaceutical company focusing on the expression of human recombinant proteins in plant cell cultures. Adv. Shahaf was a part of the founding and management team of Clal Biotechnology Industries Ltd. - Israel's largest corporate investor in the life sciences, where he served as VP and general counsel, and participated in the management and investment of over \$ 100 M.

Adv. Shahaf received his law degree from Tel Aviv University, and his MBA from the Stern School of Business at New York University, with a major in finance and international business.



## Portfolio Companies



**Enlivex's** phase I/IIa clinical study in GvHD is ongoing and expected to be completed by Q1 2012. Simultaneously, research on animal models with solid organ transplants and Crohn's Disease is under way. **Seeking external investment.**

92%



**Thrombotech's** lead compound is a safer thrombolytic agents that also extends the window of time for stroke treatment. Completed phase I successfully and has begun a multi centered international phase II trial.

25%



**ProtAb** is developing novel therapeutics for the treatment of RA and IBD. After promising results from animal studies manufacturing of humanized mAb has been completed and final tests and preparations are being made for a phase I/IIa clinical trial expected to start in early 2012. **Received \$4 M investment.**

70%



**BioMarCare** is a cancer diagnostics company developing kits using tumor biomarkers for early detection, prognosis and monitoring of cancer. Phase I completion expected Q1 2012. **Seeking external investment.**

87%



**CellCure** develops stem cell therapies for retinal and neural degenerative diseases. TEVA and BioTime, leading companies in the field, are collaborators and TEVA has a license agreement to develop and commercialize OpRegen™ for transplantation in patients with AMD which may become the first hESC based product in clinical trials.

26%



**KAHR Medical** is developing a novel fusion protein for the treatment of cancer and autoimmune diseases. A recent investment by the European pharmaceutical giant, Sanofi, and others strengthens the companies scientific and commercial value while securing a most significant strategic partner.

69.5%

### Recent achievements

**KAHR** - European drug giant, Sanofi, invested \$2 M and committed another \$1 M to a second round of financing

**Foreign Trading** - HBL initiated an American Depositary Receipt (ADR) program (OTC: HADSY) with the Bank of New York, enabling trading of the TASE shares in the US.

**Enlivex**- nearing completion of its phase III clinical trial with promising safety and efficacy results in treating GvHD in bone marrow transplant patients.

**ProtAb** - raised \$4 M from leading biotech investment groups - Pontifax Fund LP, HBL and Clal Biotechnology Industries Ltd., resulting in a major capital gain in Q2 2010.

**ThromboTech** - successfully completed a Phase I trial and has begun a multi national Phase II, with centers in Israel, Europe and the US.

**BioMarCare** - Received a \$ 900 K grant from the prestigious Binational Industrial Research and Development (BIRD) foundation for a collaboration with Ariadne Inc. to develop a diagnostic colorectal cancer test.

### Investment Criteria

HBL highly qualified BOD and scientific committee composed of key opinion leaders in the Biotechnology sector (Prof. Ruth Arnon, Prof. Tak Mak, Mr. Jonathan Silverstein, Mr. Steve Burrill).

- All companies have established proof of concept via animal model testing.
- All companies are addressing Block Buster markets.
- HBL has significant holdings and influence on the company.

### Future development

- Regularly evaluating new IP and research breakthroughs from Hadassah for the most promising technologies.
- Reviewing potential Medical Devices and opportunities to establish a Medical Device subsidiary.
- Expanding presence in the US market.

